Galectin Therapeutics Inc. (GALT)
| Previous close | 3.0600 |
| Open | 2.9900 |
| Bid | 3.3400 x 100 |
| Ask | 3.4400 x 100 |
| Day's range | 2.9900 - 3.5500 |
| 52-week range | 1.2800 - 4.2700 |
| Volume | |
| Avg. volume | 146,708 |
| Market cap | 209.854M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7400 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosisFifth positive recommendation further supports favorable tolerability and safety profile of belapectinInterim Phase 2b efficacy readout anticipated in Q4 2024 NORCROSS, Ga., April 09, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of
- GuruFocus.com
Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
Comparing GALT's Performance Against Analyst Estimates and Exploring Future Prospects
- GlobeNewswire
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program. We completed enr
